Developing a new treatment for Sjögren’s syndrome using a CD40 antagonist.
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.
['FUNDING_SBIR_2'] · BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC. · NIH-11228815
This study is looking at a new treatment called BITT-101 for people with Sjögren’s syndrome, which can cause dryness and pain, and it aims to see if this treatment is safe and effective for helping manage your symptoms.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (WINCHESTER, UNITED STATES) |
| Trial ID | NIH-11228815 on ClinicalTrials.gov |
What this research studies
This research focuses on Sjögren’s syndrome, a debilitating autoimmune disease that causes dryness and pain due to the destruction of salivary and lacrimal glands. The study aims to advance BITT-101, a novel CD40 antagonist that targets a key pathway involved in B-cell activation, which has shown promise in preclinical models. By stabilizing the inactive form of CD40, BITT-101 seeks to block harmful interactions that can lead to severe complications. Patients may have the opportunity to participate in trials assessing the safety and efficacy of this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Sjögren’s syndrome who are experiencing significant symptoms and have not responded to existing treatments.
Not a fit: Patients with other autoimmune disorders unrelated to Sjögren’s syndrome may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from Sjögren’s syndrome.
How similar studies have performed: While targeting the CD40 pathway has shown promise in preclinical models, the approach with BITT-101 is novel and has not been extensively tested in clinical settings.
Where this research is happening
WINCHESTER, UNITED STATES
- BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC. — WINCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OLIVIER, KENNETH — BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC.
- Study coordinator: OLIVIER, KENNETH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease